In this issue:
- Nivolumab plus chemotherapy in resectable disease
- Trastuzumab deruxtecan in HER2-mutant NSCLC
- Optimal duration of ICI therapy for NSCLC
- PPIs and the efficacy of EGFR-TKIs
- PPIs and the efficacy of ICIs
- Nivolumab plus ipilimumab in advanced NSCLC
- COVID-19 vaccine in patients with thoracic cancer
- Segmentectomy vs lobectomy in small-sized NSCLC
- CT screening lung cancer stage shift and survival
- Low-dose aspirin and incidence of lung cancer
Please login below to download this issue (PDF)